Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis.

STAINES-UPON-THAMES, United Kingdom, April 24, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today celebrated the completion of its expanded operations and manufacturing facility for the investigational StrataGraft® regenerative skin tissue, in Madison, Wis. Stratatech, a Mallinckrodt company, recently completed patient enrollment in its ongoing pivotal Phase 3 clinical trial, which is evaluating the efficacy and safety of StrataGraft in the promotion of autologous skin regeneration of complex skin defects due to severe thermal burns that contain intact dermal elements (also known as deep partial-thickness burns). The safety and effectiveness of StrataGraft have not yet been established by the U.S. Food and Drug Administration (FDA)...

   ...more

Ken Notes: Madison and Bio Tech are good for Wisconsin. We need to explore ways to keep our graduates and products in the state. have we ever thought of moving Aaron Oliver to an ED position, I understand he is good for the Research Park and WARF but bringing research and bio mainstream may not be a bad thing...



- - Volume: 7 - WEEK: 17 Date: 4/25/2019 9:25:59 AM -